GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of my hs-CRP moved and I cannot work out whether FLOW is why — 44 comments in the full submission. View in context.
2.2k
c/trialwatch·submitted 7 months ago by u/curious_panel_only

my hs-CRP moved and I cannot work out whether FLOW is why

Trial Databranch of 19 comments

Right, the SURMOUNT question again, but with numbers this time. I have 23 data points over 10 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am…

Read the full submission and all 44 comments →

This branch

19 comments, started 7 months ago
u/cesar_ivaturi126 points·7 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/yara_mensah41 points·7 months ago

Small correction: the trial was 13 weeks, not 6. Does not change your point but people will quote it.

replysharereportpermalink
u/curious_panel_onlyOP22 points·7 months ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
[deleted]16 points·7 months ago

[deleted]

replysharereportpermalink
u/curious_panel_onlyOP11 points·7 months ago

SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/sanne_laurent3 points·7 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/camila_vasquez8 points·7 months ago

absolute risk reduction, not relative risk reduction, that is how you decide

Disagree on that part. 98.0% and 98.1% on the same vial is normal.

replysharereportpermalink
u/milan_mensah48 points·7 months ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/arne_ilunga28 points·7 months ago

the relative risk reduction in headlines is not the whole story

Adding to this: SELECT is doing more work than the comment implies.

replysharereportpermalink
u/aurel_mwangi10 points·7 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/rt_shift_reggie25 points·7 months ago

press release hazard ratio posts must be flaired until a publication exists

replysharereportpermalink
u/blunt_coldbox_notes13 points·7 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/customs_seizure_sid19 points·7 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/niels_norgaard10 points·7 months ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/joaquin_trevino157 points·7 months ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/rohan_steiner36 points·7 months ago

That is net peptide content, not purity.

Yes, exactly this, and it is the bit that took me 73 weeks to accept.

replysharereportpermalink
u/nordic_pricing84 points·7 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/heart_rate_bump41 points·7 months ago

Phase 2 or phase 3?

replysharereportpermalink
u/line_demir34 points·7 months ago

the 18 week readout is different from the 27 week readout

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.